CA
SYRE icon

Cliff Asness’s Spyre Therapeutics SYRE Stock Holding History

Cliff Asness’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.04M Buy
22,937
+2,063
+10% +$151K ﹤0.01% 2608
2026
Q1 		$1.05M Buy
20,874
+3,054
+17% +$115K ﹤0.01% 2737
2025
Q4 		$584K Buy
17,820
+773
+5% +$20.2K ﹤0.01% 2830
2025
Q3 		$286K Sell
17,047
-926
-5% -$15.1K ﹤0.01% 3106
2025
Q2 		$269K Buy
+17,973
New +$266K ﹤0.01% 2920
2024
Q4 		– Sell
-35,003
Closed -$1.03M – 2949
2024
Q3 		$1.03M Buy
+35,003
New +$975K ﹤0.01% 1834
2022
Q2 		– Sell
-1,471
Closed -$85K – 2294
2022
Q1 		$85K Buy
+1,471
New +$124K ﹤0.01% 2148
2019
Q4 		– Sell
-428
Closed -$82K – 2177
2019
Q3 		$82K Sell
428
-410
-49% -$79.9K ﹤0.01% 2090
2019
Q2 		$143K Sell
838
-294
-26% -$50.8K ﹤0.01% 2013
2019
Q1 		$228K Hold
1,132
– – ﹤0.01% 2042
2018
Q4 		$212K Hold
1,132
– – ﹤0.01% 2060
2018
Q3 		$271K Buy
1,132
+335
+42% +$78.2K ﹤0.01% 2132
2018
Q2 		$211K Buy
+797
New +$196K ﹤0.01% 2211

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Cliff Asness's SYRE Position: Q2 2026 in Review

Cliff Asness increased its Spyre Therapeutics (SYRE) stake by 9.9% in Q2 2026, buying an estimated $151K and bringing the position to 22,937 shares worth $2.04M. The position accounts for ﹤0.01% of the portfolio, ranked #2608.

Cliff Asness first reported a position in SYRE in Q2 2018 and has held it in 13 quarters since. 263 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Cliff Asness held 22,937 shares of Spyre Therapeutics worth $2.04M as of Q2 2026.
  • Cliff Asness bought 2,063 Spyre Therapeutics shares in Q2 2026, an estimated $151K.
  • Spyre Therapeutics made up ﹤0.01% of Cliff Asness's portfolio in Q2 2026, its #2608 holding.
  • Cliff Asness first reported a position in Spyre Therapeutics in Q2 2018 and has held it in 13 quarters since.
  • 263 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.